Thursday’s Midday Stock Update: Clovis Oncology (CLVS), Anthera Pharmaceuticals (ANTH), Agenus Inc (AGEN), Calumet Specialty Products (CLMT), NovaBay Pharma (NBY)

By Carrie Williams

So far Thursday, August 8, NASDAQ is up 4.09% and the S&P is up 2.96%. Here are this morning’s most active stocks: Clovis Oncology (CLVSResearch Report), Anthera Pharmaceuticals (ANTHResearch Report), Agenus Inc (AGENResearch Report), Calumet Specialty Products (CLMTResearch Report) and NovaBay Pharma (NBYResearch Report).

Clovis Oncology is down -18.11% in midday trading to $6.36. Shares opened today at $7.76. The company has a 52-week low of $6.31 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $23.57, marking a 203.74% potential upside from current levels. In a report issued on August 2, RBC analyst Kennen MacKay maintained a Buy rating on CLVS, with a price target of $26, which represents a potential upside of 235% from where the stock is currently trading. Separately, on the same day, Guggenheim’s Michael Schmidt downgraded the stock to Hold . In the last 30 days, insiders purchased $7,499 worth of CLVS shares. Over the last 3 months, the insider sentiment on Clovis Oncology has been positive based on 37 corporate insider transactions. This sentiment is higher than the average sector sentiment of insiders.

Anthera Pharmaceuticals is up 16.98% in midday trading to $0.04. Shares opened today at $0.04. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

Agenus Inc is up 15.33% in midday trading to $2.60. Shares opened today at $2.25. The company has a 52-week low of $1.54 and a 52-week high of $0.00.

See today’s analyst top recommended stocks >>

Calumet Specialty Products is down -12.53% in midday trading to $4.33. Shares opened today at $4.95. The company has a 52-week low of $1.99 and a 52-week high of $0.00.

See today’s analyst top recommended stocks >>

NovaBay Pharma is up 10.97% in midday trading to $1.14. Shares opened today at $1.03. The company has a 52-week low of $0.23 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $1.00, marking a -2.91% potential downside from current levels. In a report issued on July 29, Laidlaw analyst Francois Brisebois maintained a Hold rating on NBY, with a price target of $1, which represents a slight downside potential from current levels. Over the last 3 months, the insider sentiment on NovaBay Pharma has been negative based on 4 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Trending Stocks Based on Insider Activity >>